[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Viral origins and vaccine supply", "description": "Thanks to Robert for his excellent clinical trial report\nWHO official investigating pandemic warns world to 'manage expectations' as team leaves quarantine\n\nhttps://www.telegraph.co.uk/news/2021/01/27/official-investigating-pandmeic-origins-warns-world-manage-expectations/?WT.mc_id=e_DM1330317&WT.tsrc=email&etype=Edi_GHS_New_Daily&utmsource=email&utm_medium=Edi_GHS_New_Daily20210128&utm_campaign=DM1330317\n\nNow in Wuhan, team of 13\n\nDutch virologist, Marion Koopmans\n\nI think we really have to manage expectations, \n\nif you look at some of the earlier quests for the origins of outbreaks, \n\nthey have taken years to complete.\n\nWuhan lab staff, first victims of coronavirus?\n\nhttps://www.telegraph.co.uk/news/2021/01/16/mike-pompeo-pushes-new-claim-china-hiding-virus-origin/\n\nChinese virology laboratory, sick, Covid-like illness in autumn 2019\n\nUS, State Department, 16th January\n\nundisclosed information\n\nhas reason to believe that several researchers inside the WIV became sick in autumn 2019,\n\nbefore the first identified case, \n\nwith symptoms consistent with both Covid-19 and common seasonal illnesses\n\nLab had been carrying out research on a bat coronavirus\n\nThe CCP has prevented independent journalists, investigators, and global health authorities from interviewing researchers at the WIV\n\nChinese authorities, virus was a US military biological weapon\n\nGao Fu, Director of China\u2019s centers for disease control and prevention\n\nTalking to state media\n\nThe coronavirus wasn\u2019t found in any animal samples at seafood market in Wuhan, ground zero of the pandemic\n \nDecember\n\nBBC team\n\nVisited Yunnan to investigate a mystery illness\n\nKilled three mine workers in 2012\n\nFollowed\n\nBroken-down lorry\n\nYunnan, cave systems, jungle, site of major coronavirus research \n\nEmmanuel Macron\n\nhttps://www.bbc.co.uk/news/live/uk-55869476\n\nAstraZeneca vaccine quasi-ineffective in over 65s\n\nhttps://www.dw.com/en/coronavirus-germany-recommends-astrazeneca-vaccine-for-under-65s-only/a-56371850\n\nGermany\n\nVaccine commission, STIKO\n\nOxford AstraZeneca, only to people aged 64 and under\n\nThere is currently insufficient data to assess the efficacy of the vaccine for persons aged 65 years and older\n\nLancet, 18th November\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext\n\nIn participants who received two doses of vaccine, \n\nmedian anti-spike SARS-CoV-2 IgG responses 28 days after the boost dose were similar across the three age cohorts\n\n18\u201355 years (n = 39)\n\n56\u201369 years (n=26)\n\nmore than 70 years (n=47)\n\nBy 14 days after the boost dose, 208 (more than 99%) of 209 boosted participants had neutralising antibody responses. \n\nT-cell responses peaked at day 14 after a single standard dose of ChAdOx1 nCoV-19\n\nProfessor John Bell, Oxford University vaccine team\n\nI\u2019m not sure where he got that from\n\nOther studies proved elderly people responded just as well in other age groups\n\nthere's really persuasive evidence that this is a protective vaccine in those populations\n\n\nEuropean Medicines Agency, Oxford AZ vaccine\n\nRecommended the product for all adults\n\nhttps://www.dw.com/en/eu-approves-astrazeneca-coronavirus-vaccine/a-56378814\n\nsafe and effective at preventing COVID-19 in people from 18 years of age\n\n\nEuropean Commission\n\nhttps://ourworldindata.org/grapher/daily-covid-vaccination-doses-per-capita?tab=map&stackMode=absolute&region=World\n\nEMA authorised Pfizer, 21st December\n\nHMRA, authorised Pfizer, 2nd December\n\nEMA authorised Oxford AZ vaccine, 29th January\n\nHMRA, authorised Oxford AZ vaccine, 30th December\n\nEMA closed, 23rd December to 4th January\n\n\nhttps://www.telegraph.co.uk/politics/2021/01/28/astrazeneca-vaccine-site-belgium-raided-request-european-commission/?li_source=LI&li_medium=liftigniter-rhr\n\nIncreasing manufacturing capacity\n\nBraintree, Essex\n\nVaccine Manufacturing and Innovation Centre (VMIC), Oxfordshire\n\n\nUS\n\nhttps://www.bbc.co.uk/news/live/uk-55853003\n\nLate January, California\n\n200 Americans, evacuated from Wuhan\n\nHealth officials, US health department, did not wear proper PPE, bad optics\n\nDays later, these officials boarded commercial airlines and flew to other parts of the country\n\nNursing home deaths\n\nhttps://www.nytimes.com/2021/01/28/nyregion/nursing-home-deaths-cuomo.html#click=https://t.co/OQPU3KXJl6\n\nNew York State Attorney General, Letitia James\n\nCurrent number up to 12,743\n\nDid not include transfers to hospital\n\nConsistent discrepancies\n\nDeaths in nursing homes and long-term care facilities, about a third of deaths\n\nMr Cuomo, publication\n\nOxford, AZ, USA\n\nhttps://www.bbc.co.uk/news/live/uk-55853003\n\nAstraZeneca is ready to launch\n\nAs soon as FDA approved\n\nUS study is fully recruited\n\nNow waiting for enough Covid cases\n\nHe says he imagines this will be in February.\n\n20 minutes in NZ\n\nhttps://www.bbc.co.uk/news/world-asia-55853023\n\nQuarantine hotel worker\n\nInappropriate encounter\n\n20 minutes in a room together", "link": "https://www.youtube.com/watch?v=qgBvEYC-xkE", "date_published": "2021-01-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Two new vaccines work", "description": "Novavax \n\nhttps://www.novavax.com/covid-19-coronavirus-vaccine-candidate-updates\n\nhttps://www.gov.uk/government/news/novavax-publishes-positive-efficacy-data-for-its-covid-19-vaccine\n\nUS company, US and UK science\n\nOperation Warp Speed\n\nEngineered viral protein, with a plant-based ingredient\n\nNormal fridge\n\nUK, N = 15,000\n\nOver the age of 65, n = 4,000\n\nNVX-CoV2373 \n\nNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial\n\nFirst to Demonstrate Clinical Efficacy Against UK and South Africa Variants\n\n51% of phase 3 participants had new UK variant\n\nEfficacy against old strain = 95.6% \n\nEfficacy against new variant = 85.6% \n\nBased on 62 cases\n\n56 cases in the placebo group\n\n6 cases in the vaccine group\n\nOf the 62 cases, 61 were mild or moderate, and 1 was severe (in placebo group).\n\nSafety\n\nInterim analysis\n\nSevere, serious, and medically attended adverse events occurred at low levels\n\nBalanced between vaccine and placebo groups\n\nClive Dix, Chair, UK Vaccine Taskforce\n\nThese are spectacular results \n\nThe efficacy shown against the emerging variants is also extremely encouraging\n\nUK timelines\n\nUK, 60 million doses, second half of 2021\n\nMade in Teesside, north east England\n\nFUJIFILM Diosynth Biotechnologies\u2019s facilities in Billingham\n\nCompany is planning to submit its data to the regulators\n\nOver to Medicines and Healthcare products Regulatory Agency (MHRA)\n\nJoint Committee on Vaccination and Immunisation (JCVI) \n\n\nSouth Africa Novavax Results\n\nN = 4,400\n\nPhase 2b clinical trial\n\nApproximately 92.6% of cases attributed to South Africa variant \n\nTriple mutant variant, 3 critical mutations in the receptor binding domain (RBD)\n\nMultiple mutations outside the RBD\n\n\nHIV Negative participants\n\n94% of the study population was HIV-negative\n\n60% efficacy for disease prevention\n\nOne severe case in the placebo group\n\nAll other cases mild or moderate\n\nHIV-positive participants (19% of adults)\n\n49.4% efficacy\n\nAlso about South Africa\n\nPrior infection with COVID-19 may not completely protect against subsequent infection by the South Africa escape variant\n\nVaccination with NVX-CoV2373 provided significant protection\n\nNovavax, working on a vaccine specifically targeted to the variant\n\nNovavax, US and Mexico phase 3 trial\n\nSignificant progress on PREVENT-19 Clinical Trial in US and Mexico\n\nPREVENT-19 has randomized over 16,000 participants\n\nComplete targeted enrolment of 30,000 patients in the first half of February\n\nJanssen, J and J\n\nhttps://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial\n\nAdenovirus vector\n\nFridge temperatures\n\nPhase 3, ENSEMBLE, 29th January\n\nN = 43,783\n\n468 symptomatic cases\n\nEfficacy in preventing disease\n\n66% effective overall in preventing disease\n\nUnited States, 72% efficacy\n\nLatin America, 66% \n\nSouth Africa, 57%\n\n28 days post-vaccination\n\nOnset of protection was observed as early as day 14\n\nEfficacy in preventing severe disease at 28 days\n\nGlobally, 85 % \n\nDemonstrated complete protection against COVID-related hospitalization and death, 28 days post-vaccination. \n\nIn all adults 18 years and older\n\nEfficacy against severe disease increased over time, with no cases in vaccinated participants reported after day 49\n\n\n\n\nProtection\n\nGenerally consistent across race, age groups, including adults over 60 years of age (N= 13,610)\n\nIncluding South Africa where nearly all cases B.1.351 lineage\n\nSafety Data\n\nIndependent group of experts\n\nDid not report any significant safety concerns\n\nVaccine candidate was generally well-tolerated. \n\nFever rates were 9%\n\nOverall serious adverse events (SAEs) reported were higher in participants who received placebo as compared to the active vaccine candidate\n\nNo anaphylaxis was observed\n\nRollout\n\nAbout \u00a37 per dose (not for profit)\n\nUK, ordered 30 million doses\n\n8 plants in 7 countries\n\nOver to, Medicines and Healthcare products Regulatory Agency (MHRA)\n\nJoint Committee on Vaccination and Immunisation (JCVI)", "link": "https://www.youtube.com/watch?v=ynyYvM7rzQ0", "date_published": "2021-01-29 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]